stock markets for traders. period
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$srng > volume is over the roof... what's up with her?
even earlier than I expected...
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8515439
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On October 17, 2012, Lpath, Inc. (the “Company”) issued a press release announcing that its common stock has been approved for listing on the NASDAQ Capital Market. The Company expects its common stock to commence trading on the NASDAQ Capital Market on Monday, October 22, 2012 under the ticker symbol “LPTN.” Prior to listing on NASDAQ, the Company’s common stock traded on the OTC Bulletin Board under the ticker symbol “LPTND”. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
http://seekingalpha.com/article/915681-lpath-restarts-nexus-trial-breathes-new-life-into-shares
nicezzz
impressive
$OCZ > consolidation on low volume... keep her on watch...
bcap > weeeeeeeeeeeeeeeeeeeeeee
missed it... crap... lol
vndm went to .005
ccaj > vndm needs to take his arzzz off the ask... still watchin'
ok, lets do the "math"...
I re-bought LPTN at .70 before r/s
sold half of LPTND at 6+
lowered my average to 3.80+
will ride shares to the up-listing
Would you like to continue a discussion of the 143 shares @ 5.01 sold at the first day of trading and how you "missed" them? jeez
watching CCAJ pos...
c'mon man... only a few shares sold at 5.01...
they announced r/s at .70 - this should be a starting point...
Anyways, LPTN deserves MC close to $90-100M (on NASDAQ 4sho)...
6.10 HOD > .87 pre- r/s
5.88 > .84 pre- r/s
whatever... first day of trading - 2.5K shares sold below 5.50 out of 8K shares in volume...
check current price
?
5.6 - equal to .80 pre r/s
$tagg > got a few .11ssss just 4 fun
$ALQA > thin to .058
http://finance.yahoo.com/news/alliqua-appoints-james-sapirstein-ceo-204354584.html
NEW YORK, NY--(Marketwire - Oct 3, 2012) - Alliqua, Inc. ( OTCQB : ALQA ) ("Alliqua" or the "Company"), an advanced biopharmaceutical company focused on the development, manufacturing and distribution of proprietary transdermal wound care and drug delivery technologies, today announced the appointment of James Sapirstein to the position of Chief Executive Officer of Alliqua to spearhead the Company's strategic growth plan for the future. In connection with the Mr. Saperstein's appointment, Richard Rosenblum will transition from President to Executive Co-Chairman and serve along with David Stefansky as Executive Co-Chairmen.
Commenting on the appointment, Richard Rosenblum, Executive Co-Chairman of Alliqua, stated, "As a biopharmaceutical industry veteran, Mr. Sapirstein has actively led and participated in more than 20 product launches in the U.S. and abroad, including all aspects of product development, strategic planning and global marketing. This experience coupled with his expertise in start-up and turnaround situations in the biotechnology space make him uniquely qualified to unlock the commercial value of our proprietary transdermal technology platform. We are confident in his ability to build our company into a world-class organization with numerous revenue generating opportunities."
Mr. Sapirstein, a graduate of the Rutgers University Ernest Mario School of Pharmacy, brings over twenty five years of pharmaceutical industry experience to Alliqua ranging from start-up situations to some of the largest companies in the world. After beginning his career in 1984 as a sales representative with Eli Lilly, he accepted a position at Hoffmann-LaRoche in 1987, where he served for almost a decade as part of its sales and marketing teams. He held a number of positions at Hoffmann-LaRoche, leading to his roles as Product Director and International Operations Manager, where he was actively involved with numerous product launches including Toradol® and Rocephin®. In 1996, he became the Director of International Marketing of the Infectious Disease Division at Bristol Myers Squibb ("BMS"). Mr. Sapirstein directed the international HIV product marketing strategy at BMS and was an integral part of the international launch of a number of products at BMS including Maxipime and Videx EC. He also led the efforts at BMS to establish "Secure the Future," a $100 million philanthropic campaign in Africa.
More recently, Mr. Sapirstein has become known in the industry as a start-up and turnaround specialist, mainly for his work at Gilead Sciences, Inc., Serono Laboratories, Inc., and Tobira Therapeutics, Inc. Mr. Sapirstein served in the Global Marketing group at Gilead, beginning in 2000 where he led and developed the global marketing strategy for its flagship HIV drug Viread. He played a key role in the development of the drug combination strategy that resulted in Gilead's acquisition of Triangle's nucleoside portfolio. That acquisition ultimately led to the launch of Truvada, Gilead's multi-billion dollar combination HIV drug. In 2002, he accepted the position of Executive Vice President for Serono Laboratories where he led a team of over 100 professionals to rebuild a struggling HIV and pediatric growth hormone business. In this role he increased sales of Serono's existing products several fold, while forging the U.S. commercialization of Serostim and Saizen. As CEO of privately held Tobira Therapeutics, a New Jersey based biopharmaceutical company focused on the development of novel HIV and infectious disease compounds, he was instrumental in helping to raise over $60 million in venture capital and research funding to enable Tobira to further its scientific development. As a result of those efforts, he was named one of New Jersey's top 50 most influential people in healthcare in 2010 by NJBiz.com.
Commenting on his new position, Mr. Sapirstein, CEO of Alliqua, added, "I am very excited to take the helm of Alliqua and lead this company toward the realization of what I believe is a very promising future. Having successfully launched numerous pharmaceutical products across the globe, I am particularly interested in tapping into the vast commercialization opportunities for Alliqua's transdermal platform as well as helping to expand the market opportunities for our SilverSeal® line of products. I believe the true game changer for Alliqua is the ability to use our transdermal platform to deliver a variety of drugs which can lead to numerous potential pharmaceutical industry partnerships and multiple large revenue generating opportunities. Additionally, by working with drugs currently on the market we can substantially reduce the timeframe to reach commercialization and I intend to work diligently to move this technology forward at Alliqua. I am confident that we are in the right place at the right time to build Alliqua into an elite biopharmaceutical company through internal development as well as select acquisitions and I know our whole team will be dedicated to reaching this goal for our company and its shareholders."
$ALQA > thin to .058
http://finance.yahoo.com/news/alliqua-appoints-james-sapirstein-ceo-204354584.html
NEW YORK, NY--(Marketwire - Oct 3, 2012) - Alliqua, Inc. ( OTCQB : ALQA ) ("Alliqua" or the "Company"), an advanced biopharmaceutical company focused on the development, manufacturing and distribution of proprietary transdermal wound care and drug delivery technologies, today announced the appointment of James Sapirstein to the position of Chief Executive Officer of Alliqua to spearhead the Company's strategic growth plan for the future. In connection with the Mr. Saperstein's appointment, Richard Rosenblum will transition from President to Executive Co-Chairman and serve along with David Stefansky as Executive Co-Chairmen.
Commenting on the appointment, Richard Rosenblum, Executive Co-Chairman of Alliqua, stated, "As a biopharmaceutical industry veteran, Mr. Sapirstein has actively led and participated in more than 20 product launches in the U.S. and abroad, including all aspects of product development, strategic planning and global marketing. This experience coupled with his expertise in start-up and turnaround situations in the biotechnology space make him uniquely qualified to unlock the commercial value of our proprietary transdermal technology platform. We are confident in his ability to build our company into a world-class organization with numerous revenue generating opportunities."
Mr. Sapirstein, a graduate of the Rutgers University Ernest Mario School of Pharmacy, brings over twenty five years of pharmaceutical industry experience to Alliqua ranging from start-up situations to some of the largest companies in the world. After beginning his career in 1984 as a sales representative with Eli Lilly, he accepted a position at Hoffmann-LaRoche in 1987, where he served for almost a decade as part of its sales and marketing teams. He held a number of positions at Hoffmann-LaRoche, leading to his roles as Product Director and International Operations Manager, where he was actively involved with numerous product launches including Toradol® and Rocephin®. In 1996, he became the Director of International Marketing of the Infectious Disease Division at Bristol Myers Squibb ("BMS"). Mr. Sapirstein directed the international HIV product marketing strategy at BMS and was an integral part of the international launch of a number of products at BMS including Maxipime and Videx EC. He also led the efforts at BMS to establish "Secure the Future," a $100 million philanthropic campaign in Africa.
More recently, Mr. Sapirstein has become known in the industry as a start-up and turnaround specialist, mainly for his work at Gilead Sciences, Inc., Serono Laboratories, Inc., and Tobira Therapeutics, Inc. Mr. Sapirstein served in the Global Marketing group at Gilead, beginning in 2000 where he led and developed the global marketing strategy for its flagship HIV drug Viread. He played a key role in the development of the drug combination strategy that resulted in Gilead's acquisition of Triangle's nucleoside portfolio. That acquisition ultimately led to the launch of Truvada, Gilead's multi-billion dollar combination HIV drug. In 2002, he accepted the position of Executive Vice President for Serono Laboratories where he led a team of over 100 professionals to rebuild a struggling HIV and pediatric growth hormone business. In this role he increased sales of Serono's existing products several fold, while forging the U.S. commercialization of Serostim and Saizen. As CEO of privately held Tobira Therapeutics, a New Jersey based biopharmaceutical company focused on the development of novel HIV and infectious disease compounds, he was instrumental in helping to raise over $60 million in venture capital and research funding to enable Tobira to further its scientific development. As a result of those efforts, he was named one of New Jersey's top 50 most influential people in healthcare in 2010 by NJBiz.com.
Commenting on his new position, Mr. Sapirstein, CEO of Alliqua, added, "I am very excited to take the helm of Alliqua and lead this company toward the realization of what I believe is a very promising future. Having successfully launched numerous pharmaceutical products across the globe, I am particularly interested in tapping into the vast commercialization opportunities for Alliqua's transdermal platform as well as helping to expand the market opportunities for our SilverSeal® line of products. I believe the true game changer for Alliqua is the ability to use our transdermal platform to deliver a variety of drugs which can lead to numerous potential pharmaceutical industry partnerships and multiple large revenue generating opportunities. Additionally, by working with drugs currently on the market we can substantially reduce the timeframe to reach commercialization and I intend to work diligently to move this technology forward at Alliqua. I am confident that we are in the right place at the right time to build Alliqua into an elite biopharmaceutical company through internal development as well as select acquisitions and I know our whole team will be dedicated to reaching this goal for our company and its shareholders."
Lpath Announces Reverse Split of Class A Common Stock
SAN DIEGO, CA--(Marketwire - Oct 4, 2012) - Lpath, Inc. ( OTCQB : LPTN ), the industry leader in bioactive lipid-targeted therapeutics, announced a 1-for-7 reverse split of the company's issued and outstanding Class A common stock and a corresponding decrease in the number of its authorized shares of Class A common stock. The reverse stock split will be effective as of 5:00 p.m. PDT on October 5, 2012.
"We have elected to effect a reverse stock split to help Lpath meet the listing requirements of the NASDAQ Capital Market," said Scott Pancoast, president and chief executive officer of Lpath. "We believe that a NASDAQ listing and the reverse stock split can broaden our shareholder base and increase the appeal of our stock to institutional investors. Further, these actions should provide benefits to our shareholders by improving trading liquidity in the stock, thereby enhancing long-term shareholder value."
Each shareholder's percentage ownership interest in Lpath and the proportional voting power remains unchanged after the reverse stock split. In addition, the rights and privileges of the holders of our common stock are unaffected by the reverse stock split. This reverse stock split is pursuant to a Certificate of Change filed with the State of Nevada.
As of the effective date, every seven shares of issued and outstanding common stock will be converted into one share of common stock, with all fractional shares being rounded up to the nearest whole share. The reverse stock split will reduce the number of shares of issued and outstanding Class A common stock from approximately 73.7 million pre-split to approximately 10.5 million post-split. The number of authorized shares of Class A common stock will be reduced from 200.0 million to 28.6 million. Proportional adjustments will be made to Lpath's warrants, stock options, and equity-compensation plans. The reverse stock split will have no effect on the company's authorized shares of preferred stock.
The company's common stock will trade under a new CUSIP number (548910306). The company's ticker symbol will remain unchanged, although a "D" will be placed on the LPTN ticker symbol (LPTND) for 20 business days to alert the public about the reverse stock split.
It is not necessary for shareholders of the company to exchange their existing stock certificates for new stock certificates of the company in connection with the reverse stock split, although shareholders may do so if they wish. Please direct any questions you might have concerning the reverse stock split to your broker or the company's transfer agent, Nevada Agency and Transfer Company, at (775) 322-0626.
Andy Hidalgo, CEO
610 903-0400 ext 101
good drawing
$mimv > news ah?
lmfao
$wpcs > thin like Paris...
check out $wpcs
$WPCS > up, up and away
$tagg > huge MMs swap... haven't seen anything like it for awhile...
$TAGG > any idea? all of the selling blocks are not retails...
$TAGG > huge dump 4 the last 10min... curious what's going on with this pos...
"conditional approval" is still conditional... many are still looking at SSH as a day-trading opportunity...
well, it is a good swing stock if you're playing it right...
man, check out $wpcs nasdaq's > ceo is workin' for a new credit line... stock is gonna blow-out when he'll be announcin' a deal...
moving on air... financial deal should be announced soon...
going to be a wild day